natgillin/translations-raw huggingface dataset:
If you think you have been given too much Cymevene talk to your doctor or go to hospital straight away. 
Če ste uporabili večji odmerek zdravila Cymevene, kot bi smeli Če menite, da ste dobili preveč zdravila Cymevene, se nemudoma posvetujte z zdravnikom ali pojdite v bolnišnico.
• allergic reaction - the signs may include, red itchy skin, swelling of the throat, face, lips or mouth, difficulty swallowing or breathing. 
• alergijska reakcija - med znaki so lahko rdeča, srbeča koža, oteklost žrela, obraza, ustnic ali ust, težave s požiranjem ali dihanjem.
Cymevene is a powder for solution for infusion. 
Zdravilo Cymevene je prašek za raztopino za infundiranje.
• swollen stomach 
• bolečine v trebuhu
Single-dose glass vials of 10 mL with fluoro-resin laminated rubber stopper and aluminum closure with flip-off cap. 
10-ml steklene viale z enim odmerkom, ki imajo gumijast zamašek, laminiran s fluorosmolo, in aluminijsko zaporo s snemno zaporko.
Do not administer by rapid or bolus intravenous injection because the resulting excessive plasma levels may increase the toxicity of ganciclovir. 
Ganciklovirja ne dajajte v hitri intravenski injekciji ali v bolusu, ker lahko tako nastala prekomerna koncentracija zdravila v plazmi poveča njegovo toksičnost.
If the blood cell counts are significantly reduced during therapy with ganciclovir, treatment with haematopoietic growth factors and/or discontinuation of treatment should be considered (see sections 4.4 and 4.8). 
Če se med zdravljenjem z ganciklovirjem število krvnih celic bistveno zmanjša, pride v poštev zdravljenje s hematopoetskimi rastnimi faktorji in/ali prenehanje zdravljenja (glejte poglavji 4.4 in
The following information is intended for healthcare professionals only: 
Naslednje informacije so namenjene samo zdravstvenemu osebju: NAVODILA ZA UPORABO IN RAVNANJE Z ZDRAVILOM
Men must be advised to practice barrier contraception during treatment, and for at least 90 days thereafter, unless it is certain that the female partner is not at risk of pregnancy (see sections 4.6, 4.8 and 5.3). 
Moškim je treba naročiti, da morajo med zdravljenjem in vsaj še 90 dni po zdravljenju uporabljati pregradno kontracepcijo, razen če je popolnoma gotovo, da partnerka ne more zanositi (glejte poglavja 4.6, 4.8 in
Also do this for at least 90 days after Cymevene has been stopped. 
Kontracepcijo morate uporabljati tudi še vsaj 90 dni po koncu zdravljenja z zdravilom Cymevene.
Please refer to the Summary of Product Characteristics for full prescribing information. 
Za celotne informacije za predpisovanje zdravila, prosimo, glejte povzetek glavnih značilnosti zdravila.
INSTRUCTIONS FOR USE AND HANDLING 
NAVODILA ZA UPORABO
• eczema, skin problems, itching 
• ekcem, težave s kožo, srbenje
These drugs should not be used concomitantly unless the potential benefits outweigh the potential risks (see section 4.4). 
Teh zdravil se ne sme uporabljati hkrati, razen če možne koristi odtehtajo možna tveganja (glejte poglavje 4.4).
Also do this for at least 30 days after Cymevene has been stopped. 
Kontracepcijo morate uporabljati tudi še vsaj 30 dni po koncu zdravljenja z zdravilom Cymevene.
Mean Ganciclovir systemic plasma clearance (mL/min) 
Povprečni sistemski plazemski očistek ganciklovirja (ml/min)
• kidney or liver problems 
• težave z ledvicami ali jetri
• fever, chills or night sweats 
• zvišana telesna temperatura, mrzlica ali nočno znojenje
For storage conditions of the reconstituted concentrate, see sections 6.3. 
Za pogoje shranjevanja rekonstituiranega koncentrata glejte poglavje 6.3.
The pharmacokinetics of intravenous ganciclovir in infants and children were consistent with those observed in neonates and adults. 
Farmakokinetika intravenskega ganciklovirja se je pri dojenčkih in otrocih skladala s farmakokinetiko, ugotovljeno pri novorojenčkih in odraslih.
What Cymevene looks like and contents of the pack Cymevene is a white to off white powder for concentrate for solution for infusion, supplied in a singledose glass vial, with a rubber stopper and aluminium closure with flip-off cap. 
Zdravilo Cymevene je bel ali skoraj bel prašek za koncentrat za raztopino za infundiranje, ki je na voljo v stekleni viali z enim odmerkom; viala ima gumijast zamašek in aluminijsko zaporo s snemno zaporko.
Renal impairment: It is expected that an overdose of ganciclovir could result in increased renal toxicity in patients with renal impairment (see section 4.4). 
Okvara ledvic: Pričakovati je, da lahko preveliko odmerjanje ganciklovirja pri bolnikih z okvaro ledvic poveča toksičnost za ledvice (glejte poglavje 4.4).
• allergic reaction - the signs may include red itchy skin, swelling of the throat, face, lips or mouth, 
• alergijska reakcija - med znaki so lahko rdeča, srbeča koža, oteklost žrela, obraza, ustnic ali ust,
After reconstitution: 
Po pripravi:
Powder for concentrate for solution for infusion (powder for concentrate). 
FARMACEVTSKA OBLIKA Prašek za koncentrat za raztopino za infundiranje (prašek za koncentrat).
If you or your partner becomes pregnant while using Cymevene, talk to your doctor straight away. 
Če bolnica ali partnerka bolnika med zdravljenjem z zdravilom Cymevene zanosi, se morate takoj posvetovati z zdravnikom.
Ganciclovir should not be used concomitantly with imipenem-cilastatin unless the potential benefits outweigh the potential risks (see section 4.5). 
Ganciklovirja se ne sme uporabljati hkrati z imipenem-cilastatinom, razen če možne koristi odtehtajo možna tveganja (glejte poglavje 4.5).
Based upon animal studies where aspermatogenesis was induced at ganciclovir systemic exposures below therapeutic levels, it is considered likely that ganciclovir causes inhibition of human spermatogenesis. 
Glede na študije na živalih, v katerih se je aspermatogeneza pojavila ob sistemski izpostavljenosti ganciklovirju, nižji od terapevtske, je verjetno,
It is recommended that complete blood counts including platelet counts be monitored during therapy. 
Med zdravljenjem je priporočljivo spremljati celotno krvno sliko, vključno s številom trombocitov.
The duration of prophylaxis is based on the risk of CMV disease, local treatment guidelines should be consulted. 
Trajanje profilakse je odvisno od tveganja za citomegalovirusno bolezen in upoštevati je treba lokalne smernice za zdravljenje.
In CMV-infected cells, ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, UL97. 
V celicah, okuženih s CMV, virusna proteinska kinaza UL97 najprej fosoforilira ganciklovir v ganciklovir-monofosfat.
After reconstitution Cymevene is a colourless to slightly yellowish solution, practically free from visible particles. 
Po rekonstituciji je zdravilo Cymevene brezbarvna do rumenkasta raztopina, ki je skoraj brez vidnih delcev.
The duration of maintenance therapy is based on the risk of CMV disease, local treatment guidelines should be consulted. 
Trajanje vzdrževalnega zdravljenja je odvisno od tveganja za citomegalovirusno bolezen in upoštevati je treba lokalne smernice za zdravljenje.
Creatinine clearance (mL/min) 
(ml/min)
Therefore, these drugs should be considered for concomitant use with ganciclovir only if the potential benefits outweigh the potential risks (see section 4.4). 
Zato pridejo ta zdravila v poštev za sočasno uporabo z ganciklovirjem le v primeru, da možne koristi odtehtajo možna tveganja (glejte poglavje 4.4).
• probenecid - used for gout, 
• probenecid - uporablja se za zdravljenje protina,
Cardiac arrhythmias 
motnje srčnega ritma
Caution should therefore be used when prescribing Cymevene to patients with known hypersensitivity to aciclovir or penciclovir (or to their prodrugs, valaciclovir or famciclovir respectively). 
Pri predpisovanju zdravila Cymevene bolnikom z znano preobčutljivostjo na aciklovir ali penciklovir (ali na njuni predzdravili valaciklovir oz.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 500 mg
For storage conditions after reconstitution and after dilution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po rekonstituciji in razredčenju zdravila glejte poglavje 6.3.
The majority of the reports were either not associated with any adverse reactions, or included one or more of the adverse reactions listed below: - Haematological toxicity: myelosuppression including pancytopenia, medullary aplasia, leucopenia, neutropenia, granulocytopenia - Hepatotoxicity: hepatitis, liver function disorder - Renal toxicity: worsening of haematuria in a patient with pre-existing renal impairment, acute renal failure, elevated creatinine. 
Večina poročil bodisi ni navajala nobenih neželenih učinkov bodisi so zajela enega ali več od spodaj naštetih neželenih učinkov: - Hematološka toksičnost: mielosupresija vključno s pancitopenijo, medularno aplazijo, levkopenijo,
Pharmacodynamic interactions 
Farmakokinetično medsebojno delovanje
• urine infection - signs include fever, passing urine more often, pain when passing urine 
• okužba sečil - med znaki so zvišana telesna temperatura, pogostejše odvajanje urina,
<10 mL/min 1.25 mg/kg 3x/wk after haemodialysis 
< 10 ml/min 1,25 mg/kg 3x/teden po hemodializi
Since renal function decreases with age, ganciclovir should be administered to the elderly with special consideration for their renal status (see section 4.2). 
Ker se delovanje ledvic s starostjo zmanjšuje, je treba med uporabo ganciklovirja pri starejših bolnikih posebej upoštevati stanje njihovih ledvic (glejte poglavje 4.2).
Following reconstitution of the powder, 1ml solution contains 50 mg ganciclovir. 
Po rekonstituciji praška vsebuje 1 ml raztopine 50 mg ganciklovirja.
Precaution to be taken before handling or administering the medicinal product: Since ganciclovir is considered a potential teratogen and carcinogen in humans, caution should be taken in its handling (see section 6.6). 
Ganciklovir velja pri človeku za potencialni teratogen in kancerogen, zato je pri ravnanju z njim potrebna previdnost (glejte poglavje 6.6).
• you are allergic to ganciclovir, valganciclovir or any of the other ingredients of this medicine 
• če ste alergični na ganciklovir, valganciklovir ali katero koli sestavino tega zdravila (navedeno v poglavju 6)
Didanosine plasma concentrations were found to be consistently raised when given with ganciclovir. 
Ugotovili so, da je bila med sočasno uporabo didanozina z ganciklovirjem koncentracija didanozina v plazmi dosledno zvišana.
Cymevene contains sodium 
Zdravilo Cymevene vsebuje natrij
Macular oedema Retinal detachment Vitreous floaters Eye pain 
edem makule odstop mrežnice delci v steklovini bolečine v očeh
This should be taken into consideration by patients on a controlled sodium diet. 
To morajo upoštevati bolniki na dieti z omejitvijo natrija.
White to off-white solid cake. 
Bela ali skoraj bela čvrsta pogača.
If you stop using Cymevene Do not stop using Cymevene without talking to your doctor. 
Ne prenehajte uporabljati zdravila Cymevene, ne da bi se prej posvetovali z zdravnikom.
Cymevene contains the active substance ganciclovir. 
Zdravilo Cymevene vsebuje zdravilno učinkovino ganciklovir.
Patients with Renal Impairment Undergoing Haemodialysis 
Bolniki z okvaro ledvic, zdravljeni s hemodializo
Aseptic technique should be used throughout to reconstitute lyophilised Cymevene. 
Priprava rekonstituiranega koncentrata Med celotnim postopkom rekonstitucije liofiliziranega zdravila Cymevene je treba uporabljati aseptično tehniko.
What Cymevene is and what it is used for 
Kaj je zdravilo Cymevene in za kaj ga uporabljamo Kaj je zdravilo Cymevene
• low level of platelets - signs include bleeding or bruising more easily than usual, blood in urine or stools or bleeding from gums, the bleeding could be severe. 
• majhno število trombocitov (krvnih ploščic) - med znaki so večja nagnjenost h krvavitvam ali podplutbam kot po navadi, kri v urinu ali blatu ali krvavitev iz dlesni; krvavitev je lahko huda.
• changes to your sense of touch, tingling, tickling, pricking or burning feeling 
• spremembe v zaznavanju dotika, mravljinčenje, draženje, zbadanje ali pekoč občutek • napadi krčev
Contents of the pack and other information 
Shranjevanje zdravila Cymevene Vsebina pakiranja in dodatne informacije
• low level of platelets - signs include bleeding or bruising more easily than usual, blood in urine or stools or bleeding from gums, the bleeding could be severe 
• majhno število trombocitov (krvnih ploščic) - med znaki so večja nagnjenost h krvavitvam ali podplutbam kot po navadi, kri v urinu ali blatu ali krvavitev iz dlesni; krvavitev je lahko huda,
Convulsions have been reported in patients taking ganciclovir and imipenem−cilastatin concomitantly. 
Pri bolnikih, ki so sočasno uporabljali ganciklovir in imipenem−cilastatin, so poročali o konvulzijah.
Confusional state Thinking abnormal 
depresija anksioznost stanje zmedenosti nenormalno mišljenje
5 mg/kg given as an intravenous infusion over one hour, once daily on 7 days per week or 6 mg/kg once daily on 5 days per week. 
5 mg/kg v intravenski infuziji v teku ene ure enkrat na dan 7 dni na teden ali 6 mg/kg enkrat na dan 5 dni na teden.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before using Cymevene. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se pred začetkom uporabe zdravila Cymevene posvetujte z zdravnikom ali farmacevtom.
- Induction treatment: 5 mg/kg given as an intravenous infusion over one hour, every 12 hours for 1421 days. 
- Indukcijsko zdravljenje: 5 mg/kg v intravenski infuziji v teku ene ure, vsakih 12 ur od 14 do 21 dni.
Formal safety studies with ganciclovir have not been conducted in children under 12 years of age but based on experience with valganciclovir, a pro-drug of ganciclovir, the overall safety profile of the active drug is similar in paediatric and adult patients. 
Toda na podlagi izkušenj z valganciklovirjem, predzdravilom ganciklovirja, so splošne varnostne značilnosti aktivnega zdravila pri pediatričnih in odraslih bolnikih podobne.
METHOD AND ROUTE(S) OF ADMINISTRATION For intravenous use after reconstitution and dilution. 
za intravensko uporabo po rekonstituciji in razredčenju
Ganciclovir causes impaired fertility and teratogenicity in animals. 
Ganciklovir pri živalih poslabša plodnost in je teratogen.
During the first 14 days of administration it is recommended that white blood cell count (preferably as a differential test) is conducted every second day; in patients with low baseline neutrophil levels (< 1000 neutrophils/µl), those who developed leucopenia during previous therapy with other myelotoxic substances, and those with renal impairment, this monitoring should be performed daily. 
Bolnikom z majhnim izhodiščnim številom nevtrofilcev (< 1000 nevtrofilcev/µl), bolnikom, ki se jim je levkopenija pojavila med predhodnim zdravljenjem z drugimi mielotoksičnimi snovmi, in bolnikom z okvaro ledvic je treba krvno sliko kontrolirati vsak dan.
Ganciclovir may have a major influence on the ability to drive and use machines (see section 4.8). 
4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Ganciklovir ima lahko pomemben vpliv na sposobnost vožnje in upravljanja s stroji (glejte poglavje
None of the ganciclovir recipients had worsening hearing from baseline to 6 months, compared with 7 control patients (p < 0.01). 
Sluh se od izhodišča do 6. meseca ni poslabšal pri nobenem prejemniku ganciklovirja, poslabšal pa se je pri 7 kontrolnih bolnikih
Reconstituted solutions of Cymevene range in colour from colourless to light yellow. 
Barva rekonstituirane raztopine zdravila Cymevene je od brezbarvne do rumenkaste.
Back pain Myalgia Arthralgia Muscle spasms 
bolečina v hrbtu mialgija artralgija spazmi mišic
days after discontinuation of the drug or dose reduction (see section 4.4). 
Število celic se po navadi normalizira v 2 do 5 dneh po prenehanju uporabe zdravila ali zmanjšanju odmerka (glejte poglavje 4.4).
• low red blood cell counts - signs include feeling short of breath or tired, palpitations or pale skin. 
• majhno število rdečih krvnih celic - med znaki so občutek kratke sape ali utrujenost, razbijanje srca (palpitacije) ali bledica kože,
Respiratory, thoracic and mediastinal disorders: Very common (≥ 1/10): 
Bolezni dihal, prsnega koša in mediastinalnega prostora: Zelo pogosti (≥ 1/10):
If any of the above apply to you (or you are not sure), talk to your doctor, pharmacist or nurse before using Cymevene. 
Če kaj od naštetega velja za vas (ali če ste negotovi), se pred začetkom uporabe zdravila Cymevene posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
Maintenance therapy: 5 mg/kg given as an intravenous infusion over one hour, once daily on 7 days per week or 6 mg/kg once daily on 5 days per week. 
Vzdrževalno zdravljenje: 5 mg/kg v enourni intravenski infuziji enkrat na dan 7 dni na teden ali 6 mg/kg enkrat na dan 5 dni na teden.
Do not use Cymevene if you are breast-feeding. 
Ne uporabljajte zdravila Cymevene, če dojite.
In a Phase III, randomised, controlled study, 100 neonates (3-33 days of age, median age 12 days) with severe symptomatic congenital CMV with CNS involvement, received either intravenous ganciclovir 6 mg/kg twice daily for 6 weeks (n = 48) or no antiviral treatment (n = 52). 
V randomizirani, kontrolirani študiji III. faze je 100 novorojenčkov (starih od 3 do 33 dni, mediana starost 12 dni), ki so imeli hudo, simptomatsko kongenitalno citomegalovirusno bolezen z zajetostjo osrednjega živčevja, prejemalo bodisi intravenski ganciklovir 6 mg/kg dvakrat na dan 6 tednov
Dose modifications for patients with renal impairment: 
Prilagoditev odmerka pri bolnikih z okvaro ledvic
- Gastrointestinal toxicity: abdominal pain, diarrhoea, vomiting - Neurotoxicity: generalised tremor, convulsion 
- Gastrointestinalna toksičnost: bolečine v trebuhu, driska, bruhanje.
0.625 mg/kg 3x/wk after haemodialysis 
0,625 mg/kg 3x/teden po hemodializi
INFORMATION IN BRAILLE Justification for not including Braille accepted [To be completed nationally] 
PODATKI V BRAILLOVI PISAVI Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
In a retrospective analysis, the safety and efficacy of ganciclovir was compared to valganciclovir in 92 paediatric kidney and/or liver transplant patients (7 months -18 years of age, median age 9 years). 
92 pediatričnih prejemnikih presajene ledvice in/ali jeter (starih od 7 mesecev do 18 let, mediana starost 9 let).
What Cymevene is used for 
Za kaj uporabljamo zdravilo Cymevene
The mean systemic clearance ranged from 2.64 ± 0.38 mL/min/kg (N = 15) to 4.52 ± 2.79 mL/min/kg (N = 6) and renal clearance ranged from 2.57 ± 0.69 mL/min/kg (N = 15) to 3.48 ± 0.68 mL/min/kg (N = 20), corresponding to 90%−101% of administered ganciclovir. 
2,79 ml/min/kg (n = 6) in ledvični očistek je segal od 2,57 ± 0,69 ml/min/kg (n = 15) do 3,48 ±
Therefore, adverse drug reactions reported with intravenous or oral ganciclovir or with valganciclovir are included in the table of adverse reactions. 
Zato so v preglednico neželenih učinkov vključeni neželeni učinki, zabeleženi z intravenskim in peroralnim ganciklovirjem ali z valganciklovirjem.
>70 mL/min 5.0 mg/kg q12h 
> 70 ml/min 5,0 mg/kg na 12 ur
Driving and using machines 
orodij ali strojev.
Each glass vial contains 500 mg ganciclovir as ganciclovir sodium. 
Ena viala vsebuje 500 mg ganciklovirja v obliki natrijevega ganciklovirata.
• low white blood cell counts - with signs of infection such as sore throat, mouth ulcers or a fever 
• majhno število belih krvnih celic - z znaki okužbe, npr. vnetjem žrela, razjedami v ustih ali zvišano telesno temperaturo
0.625 mg/kg/day 
0,625 mg/kg/dan
Cymevene contains 43 mg of sodium in each 500mg dose. 
En 500-mg odmerek zdravila Cymevene vsebuje 43 mg natrija.
Abdominal distention Mouth ulceration Pancreatitis 
napihnjenost trebuha razjede v ustih pankreatitis
In patients with mild, moderate, and severe renal impairment, mean systemic clearances of 2.1, 1 and 0.3 mL/min/kg were observed. 
Povprečni sistemski očistek je bil pri bolnikih z blago okvaro ledvic 2,1 ml/min/kg, z zmerno okvaro ledvic 1 ml/min/kg in s hudo okvaro ledvic 0,3 ml/min/kg.
The corresponding values of mean systemic clearance, mean renal clearance, and mean elimination half-life were 4.66 ± 1.72 mL/min/kg, 3.49 ± 2.40 mL/min/kg, and 2.49 ± 0.57 h, respectively. 
Ustrezna vrednost povprečnega sistemskega očistka je bila 4,66 ± 1,72 ml/min/kg, povprečnega ledvičnega očistka 3,49 ± 2,40 ml/min/kg in povprečnega eliminacijskega razpolovnega časa 2,49 ± 0,57 ure.
Induction therapy: 5 mg/kg given as an intravenous infusion over one hour, every 12 hours for 7 - 14 days. 
Indukcijsko zdravljenje: 5 mg/kg v enourni intravenski infuziji vsakih 12 ur od 7 do 14 dni.
Add a volume of 100ml of diluent to the reconstituted solution. 
Rekonstituirani raztopini dodajte 100 ml vehikla.
At intravenous doses of 5 and 10 mg/kg/day, an increase in the AUC of didanosine ranging from 38% to 67% has been observed. 
AUC didanozina od 38 % do 67 %.
If you are not sure, talk to your doctor, pharmacist or nurse before using Cymevene. 
Če ste negotovi, se pred začetkom uporabe zdravila Cymevene posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
If you are a woman who could get pregnant - use contraception while you are using Cymevene. 
Če ste ženska v rodni dobi (tj. bi lahko zanosili), morate med zdravljenjem z zdravilom
Hypersensitivity to the active substance or valganciclovir or to any of the excipients listed in section 
Preobčutljivost za zdravilno učinkovino, valganciklovir ali katero koli pomožno snov, navedeno v poglavju 6.1.
What you need to know before you use Cymevene 
Kaj morate vedeti, preden boste uporabili zdravilo Cymevene Ne uporabljajte zdravila Cymevene:
NAME OF THE MEDICINAL PRODUCT {(Invented) name and associated names (see Annex I) strength pharmaceutical form} [See Annex I - To be completed nationally] 
IME ZDRAVILA {(Izmišljeno) ime in povezana imena (glejte Prilogo I) jakost farmacevtska oblika}
• your weight 
• vaše starosti,
(listed in section 6) 
(glejte poglavji 4.4 in 4.5).
prevention of CMV disease in patients with drug-induced immunosuppression (for example following organ transplantation or cancer chemotherapy). 
(na primer po presaditvi organa ali kemoterapiji raka).
Estimated creatinine clearance can be calculated from serum creatinine using the following formulae: For males: (140 - age [years]) x (body weight [kg]) 
Za moške: (140 - starost [leta]) x (telesna masa [kg])
Blood creatinine increased 
Očistek kreatinina
Induction dose 
Indukcijski odmerek
OTHER SPECIAL WARNING(S), IF NECESSARY Avoid direct contact with or inhalation of the powder contained in the vial or direct contact of the solution with skin or mucous membranes. 
Izogibajte se neposrednemu stiku ali vdihavanju praška v viali in neposrednemu stiku raztopine s kožo ali sluznicami.
How often you will have Cymevene and how long you keep using it will also vary. 
Različna je tudi pogostnost uporabe zdravila Cymevene in trajanje zdravljenja z njim.
50-69 mL/min 2.5 mg/kg q12h 
50-69 ml/min 2,5 mg/kg na 12 ur
Creatinine clearance renal decreased Renal impairment 
zmanjšan očistek kreatinina okvara ledvic zvišanje kreatinina v krvi
• stomach pain, constipation, wind, indigestion 
• izguba apetita, neješčnost ali hujšanje • bolečine v trebuhu, zaprtost, vetrovi, težave z želodcem
Common: may affect up to 1 in 10 people 
Pogosti: pojavijo se lahko pri do 1 od 10 bolnikov
QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains 500 mg of ganciclovir (as ganciclovir sodium). 
Ena viala vsebuje 500 mg ganciklovirja (v obliki natrijevega ganciklovirata).
How to store Cymevene 
Shranjevanje zdravila Cymevene
Convulsions have been reported in patients taking imipenem-cilastatin and ganciclovir. 
Pri bolnikih, ki so sočasno uporabljali imipenem-cilastatin in ganciklovir, so poročali o konvulzijah.
Cymevene should be used with caution in patients with pre-existing haematological cytopenia or a history of drug-related haematological cytopenia and in patients receiving radiotherapy. 
bolnikih z anamnezo hematološke citopenije, povezane z zdravili, in bolnikih, ki prejemajo radioterapijo.
Common (≥ 1/100, <1/10): 
Pogosti (≥ 1/100, < 1/10):